New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 27, 2014
08:08 EDTCLSNCelsion announces positive results from Phase III HEAT Study of ThermoDox
Celsion announced that the latest overall survival data from its post-hoc analysis of results from the Company's Phase III HEAT Study of ThermoDox, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin in combination with radio frequency ablation, supports the continued clinical development of ThermoDox in a prospective pivotal Phase III Study, subject to regulatory review and agreement. As provided for in the HEAT Study's Special Protocol Assessment, or SPA, agreement with the FDA the Company continues to follow patients for overall survival, the secondary endpoint of the Study. Data from four quarterly reviews of overall survival have been evaluated since the announcement of top line PFS data.
News For CLSN From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 30, 2014
10:02 EDTCLSNOn The Fly: Analyst Initiation Summary
Subscribe for More Information
06:57 EDTCLSNCelsion initiated with a Buy at Cantor
Subscribe for More Information
October 29, 2014
08:18 EDTCLSNCelsion presents positive data for its Therasilence platform
Celsion presented data related to TheraSilence, its lung-specific RNA delivery technology, at the miRNA World Conference Workshop on miRNA Delivery in Boston, MA. The data highlighted formulation characteristics of the TheraSilence delivery platform, preclinical proof-of concept data and data supportive of GEN-2, Celsion's RNA interference therapeutic for the treatment of lung cancer. Celsion acquired the TheraSilence platform and GEN-2 through its acquisition of EGEN, Inc. in June. Intravenous delivery of RNA inhibiting VEGFR-2, a tumor angiogenesis factor, with the TheraSilence delivery system resulted in significant knockdown of VEGFR-2 transcript in lungs, reduction in tumor blood vessel density and inhibition of tumor growth. Systemically administered RNA complexes using the TheraSilence delivery system demonstrated a good tolerability profile.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use